AngioDynamics Inc (ANGO)

Currency in USD
11.23
-2.96(-20.86%)
Closed·
11.230.00(0.00%)
·
ANGO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.0613.80
52 wk Range
9.3916.29
Key Statistics
Prev. Close
11.23
Open
13.22
Day's Range
11.06-13.8
52 wk Range
9.39-16.29
Volume
3.07M
Average Volume (3m)
552.96K
1-Year Change
0.8079%
Book Value / Share
4.1
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANGO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.00
Upside
+78.09%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

AngioDynamics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.00
(+78.09% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy19.00+69.19%16.00MaintainJul 16, 2026
Freedom Broker
Buy17.00+51.38%16.00MaintainJul 15, 2026
Canaccord
Buy20.00+78.09%16.00MaintainJul 14, 2026
Freedom Broker
Buy16.00+42.48%-New CoverageApr 06, 2026
Canaccord
Buy16.00+42.48%18.00MaintainApr 06, 2026

AngioDynamics Inc Earnings Call Summary for Q1/2027

  • AngioDynamics posted Q1 FY2027 adjusted loss of $0.04/share, beating estimates of $0.11 loss; revenue rose 6.9% to $80.9M vs. $80.5M forecast.
  • Gross margin expanded 410bps to 59.4% driven by product mix and tariff refunds; Med Tech revenue grew 13.2% to $39.9M, nearing 49% of total sales.
  • Company maintained FY2027 guidance: revenue $336-341M (5-6.5% growth), Med Tech growth 12-15%, adjusted EBITDA $13-16M, positive operating cash flow.
  • Shares fell 2.96% premarket to $13.77 despite earnings beat, as investors weighed modest revenue growth and continued Q1 cash outflow concerns.
  • CEO Clemmer highlighted 21 consecutive quarters of double-digit growth in key products; analysts remain optimistic with price targets of $17-24.
Last Updated: 08/10/2026, 13:52
Read Full Transcript

Earnings

Latest Release
Oct 08, 2026
EPS / Forecast
-0.04 / -0.11
Revenue / Forecast
80.9M / 80.5M
EPS Revisions
Last 90 days

ANGO Income Statement

Compare ANGO to Peers and Sector

Metrics to compare
ANGO
Peers
Sector
Relationship
P/E Ratio
−12.6x−45.3x−0.3x
PEG Ratio
2.52−2.070.00
Price/Book
2.7x2.9x2.6x
Price / LTM Sales
1.4x2.8x3.0x
Upside (Analyst Target)
40.9%98.7%62.0%
Fair Value Upside
Unlock7.2%8.2%Unlock

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
12.43M30.07%176.38M
Other Institutional Investors
30.85M69.93%437.74M
Public Companies & Retail Investors
0.000.00%0.00
Total
43.28M100.00%614.12M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.20%3,803,23253,968
Point72 Asset Management, L.P.7.41%3,062,51743,457

People Also Watch

120.8900
RBRK
-2.30%
113.20
CRUS
+0.46%
71.57
PENG
-1.43%
72.93
TTAN
+1.66%
38.28
PRGS
+2.88%

FAQ

What Is the AngioDynamics (ANGO) Stock Price Today?

The AngioDynamics stock price today is 11.23 USD.

What Stock Exchange Does AngioDynamics Trade On?

AngioDynamics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for AngioDynamics?

The stock symbol for AngioDynamics is "ANGO."

What Is the AngioDynamics Market Cap?

As of today, AngioDynamics market cap is 464.16M USD.

What Is AngioDynamics's Earnings Per Share (TTM)?

The AngioDynamics EPS (TTM) is -0.88.

When Is the Next AngioDynamics Earnings Date?

AngioDynamics will release its next earnings report on Jan 07, 2027.

From a Technical Analysis Perspective, Is ANGO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has AngioDynamics Stock Split?

AngioDynamics has split 0 times.

How Many Employees Does AngioDynamics Have?

AngioDynamics has 632 employees.

What is the current trading status of AngioDynamics (ANGO)?

As of Oct 09, 2026, AngioDynamics (ANGO) is trading at a price of 11.23 USD, with a previous close of 11.23 USD. The stock has fluctuated within a day range of 11.06 USD to 13.80 USD, while its 52-week range spans from 9.39 USD to 16.29 USD.

What Is AngioDynamics (ANGO) Price Target According to Analysts?

The average 12-month price target for AngioDynamics is 20.00 USD, with a high estimate of 24 USD and a low estimate of 17 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +78.09% Upside potential.

What Is the ANGO Premarket Price?

ANGO's last pre-market stock price is 12.84 USD. The pre-market share volume is 115,570.00, and the stock has decreased by -1.35, or -9.51%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.